The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

KING OF PRUSSIA, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced that David ...

Vertex Pharmaceuticals (VRTX) shares have been fairly steady recently, as investors digest the company’s financial performance over the past month. The stock is up 8% since early May. This reflects a ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy Trikafta, a buyers club has resurfaced with a plan to introduce a discounted ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...